Mirum Pharmaceuticals (MIRM) announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating Livmarli for the treatment of cholestatic pruritus in patients aged six months or older with rare cholestatic liver diseases, including biliary atresia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum completes enrollment in AZURE-1 study, screening in AZURE-4 study
- Mirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISI
- Mirum Pharmaceuticals reports Q4 revenue $148.93M, consensus $141.81M
- Mirum Pharmaceuticals sees FY26 global net product sales $630M-$650M
- Mirum Pharmaceuticals falls -16.5%